ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Noninvasive early differential diagnosis and progression monitoring of ovarian cancer using the copy number alterations of plasma cell-free DNA

Chen, Lu; Ma, Rong; Luo, Chang; Xie, Qin; Ning, Xin; Sun, Kaidi; Meng, Fanling*; Zhou, Meng*; Sun, Jie*哈尔滨医科大学
Translational Research2023-12DOI: 10.1016/j.trsl.2023.07.005
1被引6阅读
引用收藏
分享

摘要

Ovarian cancer (OV) is the most lethal gynecological malignancy and requires improved early detection methods and more effective intervention to achieve a better prognosis. The lack of sensitive and noninvasive biomarkers with clinical utility remains a challenge. Here, we conducted a genome-wide copy number variation (CNV) profil -ing analysis using low-coverage whole genome sequencing (LC-WGS) of plasma cfDNA in patients with nonmalig-nant and malignant ovarian tumors and identified 10 malignancy-specific and 12 late-stage-specific CNV markers from plasma cfDNA LC-WGS data. Concordance analysis indicated a significant correlation of identified CNV markers between CNV profiles of plasma cfDNA and tissue DNA (Pearson's r = 0.64, P = 0.006 for the TCGA cohort and r = 0.51, P = 0.04 for the Dariush cohort). By leveraging these specific CNV markers and machine learning algorithms, we developed robust predictive models showing excellent performance in distinguishing between malignant and nonmalignant ovarian tumors with F1-scores of 0.90 and ranging from 0.75 to 0.99, and prediction accuracy of 0.89 and ranging from 0.66 to 0.98, respectively, as well as between early-and late-stage ovarian tumors with F1-scores of 0.84 and ranging from 0.61 to 1.00, and prediction accuracy of 0.82 and ranging from 0.63 to 0.96 in our institute cohort and other external validation cohorts. Furthermore, we also discovered and validated certain CNV features associated with survival outcomes and platinum-based chemotherapy response in multicenter cohorts. In conclusion, our study demonstrated the clinical utility of CNV profiling in plasma cfDNA using LC-WGS as a cost-effective and accessible liquid biopsy for OV.

学科与关键词

关键词
plasma cell-free DNAnoninvasive diagnosisovarian cancerlow-coverage whole-genome sequencingprogression monitoring
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Translational Research
发表日期
2023-12
卷期
第 262 卷
页码
12-24
DOI
10.1016/j.trsl.2023.07.005
语言
ENGLISH
成果收录
SCIE
资助标注
Beijing Science and Technology Innovation Medical Development Fund; Beijing Medical Award Fund; National Natural Science Foundation of China [KC2021-JF-0055-01]; Zhejiang Provincial Natural Science Foundation of China [YXJL-2021-0577-0421]; [62272346]; [LY22C060001]

作者

  • C

    Chen, Lu (第一作者)

    harbin med univ · wenzhou med univ

  • M

    Ma, Rong

    harbin med univ

查看全部 9 位作者收起作者
  • L

    Luo, Chang

  • X

    Xie, Qin

    harbin med univ

  • N

    Ning, Xin

    harbin med univ

  • S

    Sun, Kaidi

    harbin med univ

  • M

    Meng, Fanling (通讯)

    harbin med univ

  • Z

    Zhou, Meng (通讯)

    wenzhou med univ

  • S

    Sun, Jie (通讯)

    wenzhou med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417